Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Breast 2Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Stomach Neoplasms 76Colorectal Neoplasms 28Breast Neoplasms 23Esophageal Neoplasms 20Pancreatic Neoplasms 13Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Rectal Neoplasms 9Ovarian Neoplasms 8Endometrial Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5HER2-positive Gastric Cancer 5Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms, Male 4Adenocarcinoma 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Bile Duct Neoplasms 3Vulvar Neoplasms 2

Interventions

pembrolizumab 20Gemcitabine 10Nivolumab 8Irinotecan 8atezolizumab 7durvalumab 6Docetaxel 6sargramostim 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5aldesleukin 4Psychiatric Rehabilitation 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cisplatin 4tislelizumab 3spartalizumab 3avelumab 3Topotecan 3Therapeutics 3Polymerase Chain Reaction 3Carboplatin 3Bevacizumab 3tremelimumab 2talazoparib 2surufatinib 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Trastuzumab × Gastrointestinal × Clear all
NCT00028535 2013-06-04

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡